InvestorsHub Logo
Followers 24
Posts 1614
Boards Moderated 0
Alias Born 01/02/2003

Re: Bio_Tech_Boss post# 5096

Sunday, 11/25/2007 12:18:00 PM

Sunday, November 25, 2007 12:18:00 PM

Post# of 12660
Yes, if Provenge works, the potential longer survival time of the early enrollees should have some sort of an offsetting effect. There were 179 patients enrolled as of 2/6/06. Nothing has been released about the enrollment rate before that date, although Nicole Provost presented data from 99 patients at the CTGTAC in February or March of 2006. I would estimate that there were about that many enrolled as of Feb 2005, meaning that approx 20% of the patients in the trial will have been enrolled for 45 to 65 months if the interim look happens in Nov 2008.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.